GHRP-6

GHRP-6 (Growth Hormone-Releasing Peptide-6), also known as Hexapeptide-2 or SKF-110679, is a synthetic six-amino-acid growth hormone secretagogue originally developed as an analogue of met-enkephalin. Its sequence, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, incorporates two D-amino acids and a C-terminal amide that distinguish it from naturally occurring peptides. GHRP-6 activates the growth hormone secretagogue receptor GHS-R1a, also known as the ghrelin receptor, producing rapid, dose-dependent growth hormone release. It has also demonstrated appetite-stimulating activity in animal models and can influence additional pituitary and metabolic signaling pathways.

Controlled human studies conducted since the late 1980s have demonstrated substantial GH secretion following intravenous, intranasal, and sufficiently high oral experimental doses of GHRP-6. Subsequent investigations have examined its pharmacokinetics, endocrine interactions, and diagnostic potential for GH deficiency. More recent laboratory and animal research has explored possible cardioprotective effects, kidney injury recovery, and regulation of cellular metabolism. However, these findings do not establish that GHRP-6 improves muscle growth, fat loss, athletic recovery, or longevity in humans. GHRP-6 is not FDA-approved, and its long-term therapeutic dosing and safety remain unestablished.

GHRP-6 produces its primary endocrine effects through activation of the growth hormone secretagogue receptor GHS-R1a. This receptor is involved in both pituitary growth hormone secretion and hypothalamic regulation of food intake and energy balance.

1. Ghrelin Receptor Activation

• GHRP-6 acts as an agonist of GHS-R1a, a receptor naturally activated by the hormone ghrelin.
• GHS-R1a is expressed in the pituitary, hypothalamus, and several peripheral tissues.
• Receptor activation stimulates intracellular signaling involving phospholipase C, inositol phosphates, and calcium mobilization.
• These signals contribute to growth hormone secretion and other physiological responses.
• GHRP-6 was developed before ghrelin itself was identified as the receptor's natural ligand.

2. Growth Hormone Release

• GHRP-6 stimulates the pituitary to release endogenous growth hormone.
• Early controlled human studies demonstrated rapid, dose-dependent increases in circulating GH.
• In one 1989 human study, the mean peak GH response increased from approximately 17.8 mcg/L at 0.25 mcg/kg to 63.0 mcg/L at 1 mcg/kg during intravenous infusion.
• This provides evidence of endocrine potency, but the relationship between dose and response varies with individual physiology and route.
• No universal 100 mcg ceiling has been established across all humans and administration routes.

3. Interaction With Growth Hormone-Releasing Hormone

• GHRH stimulates growth hormone secretion through a receptor distinct from GHS-R1a.
• GHRP-6 and GHRH can produce amplified GH responses when administered together in controlled human experiments.
• Some studies reported synergistic stimulation at submaximal doses.
• However, GHRP-6 still depends partly on normal hypothalamic-pituitary regulation.
• A 1998 human experiment demonstrated that GHRH receptor blockade eliminated most of the GH response to GHRP-6.

4. IGF-1 Signaling

• Growth hormone stimulates production of insulin-like growth factor-1 (IGF-1), particularly in the liver.
• IGF-1 participates in tissue growth, protein metabolism, and cellular maintenance.
• A 1991 study reported increased IGF-1 after repeated intranasal GHRP-6 administration in six healthy men.
• These changes demonstrate endocrine activity but do not independently establish improved muscle mass or tissue repair.

5. Appetite and Hypothalamic Signaling

• Ghrelin receptor signaling influences hunger, food-seeking behavior, and energy balance.
• Animal experiments demonstrate that GHRP-6 stimulates feeding-related hypothalamic pathways.
• A 2025 mouse study found that intranasal GHRP-6 increased both meal frequency and meal size.
• The study also identified activation of hypothalamic neurons expressing GHS-R and appetite-related neuropeptides such as AgRP.
• Direct human trials quantifying food intake after GHRP-6 are much more limited than studies of related agents such as GHRP-2 or native ghrelin.

6. Cortisol and Prolactin

• Although GH stimulation is GHRP-6's principal measured endocrine effect, the peptide is not completely selective.
• At higher experimental doses, some human studies reported increases in prolactin and cortisol.
• These effects vary across studies and may depend on dose, physiological state, and endocrine testing conditions.
• Therefore, GHRP-6 should not be described as free from adrenal or prolactin-related effects.

7. Glucose and Insulin Regulation

• GH and ghrelin pathways participate in glucose metabolism and energy homeostasis.
• Some human metabolic studies indicate that responses to GHRP-6 depend on fasting state and GH receptor activity.
• A controlled study using the GH receptor antagonist pegvisomant identified glucose- and insulin-related changes under specific experimental conditions.
• These findings support further metabolic research but do not establish a predictable fat-loss effect.

8. Receptor Adaptation

• GH responses may change during continuous or repeated secretagogue exposure.
• A 1993 human study found that 24-hour GHRP-6 infusion changed the response to a subsequent GHRP-6 challenge.
• Other studies demonstrated that certain GH responses remained measurable despite prolonged exposure.
• These findings indicate complex adaptation rather than a universally established tolerance threshold.
• No validated cycle or washout period exists to preserve receptor responsiveness in healthy adults.

9. Cardioprotective Signaling

• Preclinical research has investigated whether GHRP-6 can protect cardiac tissue during experimental injury.
• A 2024 rat study found reduced selected measures of doxorubicin-associated myocardial and other tissue damage.
• Researchers identified changes consistent with cellular survival and protection from injury.
• These observations do not establish effectiveness in humans receiving chemotherapy or experiencing heart disease.

10. Kidney Injury and Metabolic Reprogramming

• Kidney tubular epithelial cells are vulnerable to oxygen deprivation during acute kidney injury.
• A study first published in December 2025, appearing in a 2026 journal volume, investigated a specially engineered GHRP-6-containing hydrogel in mice.
• The experimental system influenced glutamine, spermidine, acetyl-CoA, and fatty acid metabolism.
• Researchers reported changes in mTOR/P70 signaling, cellular survival, and kidney injury-related measurements.
• This specialized hydrogel cannot be assumed equivalent to ordinary GHRP-6 injections.

The Key Difference: GHRP-6 is a potent GH secretagogue with additional metabolic and preclinical tissue-related activity. Its ability to increase hormones or alter cellular signaling does not establish clinically meaningful muscle growth, fat loss, organ protection, or longevity benefits in humans.

Researchers are interested in GHRP-6 because it provides a useful experimental tool for investigating the ghrelin receptor, growth hormone release, appetite, and potential tissue-protective mechanisms.

• Growth Hormone Secretion: Human studies demonstrate rapid and dose-dependent GH stimulation.
• GH Deficiency Diagnostics: GHRP-6 has been evaluated as a provocative test of pituitary GH reserve.
• Ghrelin Receptor Biology: Receptor studies provide insight into appetite, endocrine regulation, and cellular signaling.
• Appetite Stimulation: Animal experiments demonstrate increased food intake and activation of feeding-related neurons.
• IGF-1 Regulation: Repeated human exposure has produced changes in circulating IGF-1.
• Endocrine Interactions: Researchers study responses involving GHRH, prolactin, cortisol, and somatostatin.
• Body Composition: Animal research suggests effects on fat accumulation and energy balance.
• Cardiac Protection: Experimental studies investigate doxorubicin-associated tissue injury.
• Kidney Injury: Specialized hydrogel systems have been studied for metabolic and regenerative effects in mice.
• Neuroendocrine Research: GHRP-6 provides a model for understanding hypothalamic signaling and physiological adaptation.
• Pharmacokinetics: Human studies have characterized plasma distribution, elimination, and dose-related exposure.

Research Limitation: Most demonstrated human outcomes involve hormone measurements or diagnostic testing. Meaningful long-term therapeutic benefits for muscle mass, fat loss, appetite disorders, cardiovascular disease, and kidney injury remain unestablished.

GHRP-6 has demonstrated growth hormone-stimulating effects in controlled human studies. Its potential applications in appetite regulation, tissue protection, and metabolic health are supported mainly by animal and laboratory findings rather than clinical therapeutic trials.

Notable Human and Preclinical Research

GH Release — 1989 Human Study: Seventeen healthy men received varying intravenous doses of GHRP-6 during a 30-minute infusion. Mean peak GH concentrations were approximately 17.8 mcg/L at 0.25 mcg/kg, 38.3 mcg/L at 0.5 mcg/kg, and 63.0 mcg/L at 1 mcg/kg. The results demonstrated a substantial dose-dependent endocrine response.

GHRH Synergy — 1990 Study: A separate clinical experiment found that combining submaximal GHRP-6 doses with GHRH produced GH responses greater than would be expected from some individual administrations. This established an important interaction between the secretagogue and GHRH pathways.

Intranasal GH and IGF-1 — 1991 Research: Six healthy men underwent intravenous and intranasal GH stimulation testing. Intranasal administration produced dose-related GH increases. After seven intranasal administrations over approximately three days, average IGF-1 increased from 94.5 to 125.8 mcg/L. This provides evidence of intranasal biological activity, although it does not establish an approved nasal therapy.

Oral Activity — 1992 Research: Ten healthy men received several oral experimental doses and an intravenous comparator. Oral administration at 300 mcg/kg stimulated GH significantly more than placebo, while 30 and 100 mcg/kg did not produce statistically significant differences in pairwise comparisons. This demonstrates that oral activity is possible at sufficiently high experimental doses, even though oral delivery is considerably less efficient than IV administration.

Human Pharmacokinetics — 2013 Study: Nine healthy men received controlled intravenous GHRP-6 exposures. Researchers measured a mean distribution half-life of 7.6 minutes and an elimination half-life of approximately 2.5 hours. These are plasma pharmacokinetic findings, not evidence that biological or muscle-building effects persist for a particular duration.

GH Deficiency Testing — 2009 Study: Forty-nine patients with suspected hypothalamic or pituitary disorders underwent GHRP-6 and insulin tolerance testing, alongside 20 healthy controls receiving GHRP-6 testing. One proposed GH threshold produced approximately 80% sensitivity and 95% specificity for severe GH deficiency. This was diagnostic research, not evidence of therapeutic replacement for deficient GH secretion.

Appetite — Animal Findings: A 2004 rat study demonstrated increased feeding for several hours following GHRP-6 exposure. In a more recent mouse experiment, intranasal GHRP-6 increased both the number and size of meals. The results establish orexigenic activity in these models but do not quantify an equivalent increase in human food intake.

Body Fat — Important Animal Finding: A two-week rat study found increased body weight in GHRP-6-treated animals and approximately 15% greater subcutaneous fat-pad mass and 20% greater visceral mesenteric fat-pad mass in selected adrenal-intact animals. These findings challenge the assumption that GH stimulation from GHRP-6 reliably produces fat loss.

Heart Protection — 2024 Research: A rat study investigated GHRP-6 during doxorubicin exposure. Researchers reported improvements in selected myocardial and extra-cardiac injury measurements associated with cellular survival pathways. However, the study does not establish prevention of chemotherapy-related heart damage in human patients.

Kidney Protection — 2025–2026 Research: Investigators developed a specialized self-assembling GHRP-6 hydrogel for acute kidney injury. In mice, it was associated with changes in spermidine, glutamine, acetyl-CoA, fatty acid metabolism, and mTOR/P70 signaling, alongside improved selected renal recovery outcomes. These results do not establish benefits from ordinary subcutaneous injections or treatment of human kidney disease.

Muscle Hypertrophy: GHRP-6 increases GH, a hormone involved in protein and tissue metabolism. However, no adequately controlled human trial demonstrates that repeated GHRP-6 administration increases functional muscle mass or strength.

Fat Loss: Growth hormone may influence lipolysis, but GHRP-6 also stimulates appetite-related pathways. No rigorous human trial establishes sustained fat loss or improved body composition from routine treatment.

Recovery and Longevity: No controlled human evidence demonstrates faster injury recovery, better sleep, increased athletic performance, reversal of biological aging, or extended lifespan.

Research Perspective: GHRP-6 is a well-supported experimental GH secretagogue with additional preclinical applications. Its strongest evidence concerns hormonal activity, while long-term therapeutic outcomes remain unproven.

GHRP-6 has been administered in controlled human research through intravenous, intranasal, and oral routes. Published doses were selected to investigate GH secretion, pharmacokinetics, or pituitary diagnostic responses rather than muscle building or anti-aging. No FDA-approved therapeutic dose, daily self-injection schedule, or validated long-term treatment regimen exists.

Published Clinical Research and Community-Reported Dosing

Important Dose-Response Distinction: A fixed 100 mcg ceiling has not been established in human clinical research. Published studies investigated weight-adjusted doses and observed increases in GH responses across several concentrations. Larger doses may also increase unwanted endocrine effects.

Human Pharmacokinetic Findings

• Distribution Half-Life: Approximately 7.6 minutes in a 2013 human IV study.
• Elimination Half-Life: Approximately 2.5 hours on average, with considerable individual variability.
• Measured Exposure: Plasma exposure generally increased as the administered IV dose increased.
• Hormonal Duration: The GH response duration is not identical to the plasma elimination half-life of GHRP-6.
• Subcutaneous Bioavailability: Reliable comparative human data are insufficient to establish an equivalent dose across IV, intranasal, oral, and subcutaneous routes.

Research Concentration Mathematics

A commonly described laboratory calculation involves 10 mg of peptide in a final solution volume of 3.0 mL. Assuming the stated peptide mass and final volume are accurate, the nominal concentration is approximately 3.33 mg/mL, equivalent to 33.3 mcg per 0.01 mL. This is a mathematical example and not evidence that such a solution is suitable for injection.

Calculation Limitations: U-100 markings measure fluid volume rather than peptide mass. The presence of a nominal quantity on a research vial does not establish actual peptide content, pharmaceutical equivalence, sterility, endotoxin control, or a clinically appropriate dose.

Administration Routes

• Intravenous: The principal route used in early human dose-response studies and subsequent pharmacokinetic research.
• Intranasal: Human research has demonstrated GH stimulation. More recent mouse work investigated direct engagement of brain appetite-related pathways.
• Oral: A 1992 human study demonstrated biological activity at high experimental doses, although oral delivery required substantially more compound than the IV comparison.
• Subcutaneous: Frequently described in community protocols, but no validated clinical regimen establishes its long-term effectiveness for muscle growth, fat loss, or recovery.
• Intramuscular: No established therapeutic regimen for repeated use.

Fasting and Meal Timing

• Fasting: Human research demonstrates that prolonged fasting can alter the GH response to GHRP-6.
• Meal Effects: A clinical investigation of the combined GHRH/GHRP-6 stimulation test found that lunch did not significantly change the GH response under the tested conditions.
• Strict Timing Claims: Requirements to wait exactly one to two hours after eating or 30–60 minutes before eating are not established universal rules.
• Carbohydrates and Fats: Nutrient composition can influence GH physiology, but no controlled long-term GHRP-6 study establishes a mandatory macronutrient-related injection window.
• Insulin: Experimental endocrine responses involving insulin or GH receptor blockade do not establish that combining GHRP-6 with injected insulin is an effective or safe strategy. Insulin misuse can cause life-threatening hypoglycemia.

Formulation and Storage

• Lyophilized Material: Research suppliers often specify frozen, dry, light-protected storage for unopened powder.
• Reconstituted Material: Stability depends on pH, salts, solvents, packaging, temperature, sterility, and validated formulation data.
• Post-Mixing Shelf Life: No universal 28-day beyond-use date has been established for community-prepared GHRP-6 solutions.
• Product Quality: Peptide identity, purity, aggregates, residual manufacturing impurities, microbial contamination, and endotoxin levels are important for injectable safety.
• Research-Grade Products: A certificate of analysis describing chemical purity does not independently establish suitability for human injection.

Research Perspective: Clinical research doses, animal exposures, community quantities, and concentration mathematics are presented for scientific comparison. No approved or validated self-administration protocol exists for GHRP-6 in healthy adults.

No clinically validated treatment cycle, washout period, or long-term maintenance schedule exists for GHRP-6. Published human studies have primarily evaluated single GH-stimulation challenges, short repeated exposure, or continuous infusion for approximately one to two days.

• 1989 Clinical Research: Single 30-minute IV infusions followed by hormone measurements.
• 1991 Intranasal Research: Seven administrations over approximately three days, with IGF-1 and GH assessments.
• 1992 Oral Research: Single-dose crossover challenges separated by one-week intervals.
• 1993 Continuous Infusion Research: Included 24-hour and 34-hour human infusion studies investigating pulsatile GH secretion and receptor adaptation.
• 2002 Receptor Adaptation Research: Investigated acute sequential secretagogue responses separated by approximately two hours.
• Community Introductory Cycles: Two to four weeks of informal repeated administration are sometimes described.
• Common Community Cycles: Six to twelve weeks are frequently promoted.
• Extended Community Cycles: Some sources describe sixteen weeks of repeated exposure.
• Community Washout Periods: Two to four weeks between courses are often suggested without controlled evidence.
• Long-Term Human Safety: No large study establishes acceptable cumulative risk from repeated daily exposure over many months or years.

Receptor Adaptation: A 1993 human study demonstrated that a 24-hour GHRP-6 infusion attenuated the GH response to a subsequent GHRP-6 challenge. A later study found partial desensitization of the ghrelin-related GH response following prior GHRP-6 exposure.

Important Limitation: These observations do not establish that a two-week washout resets receptor sensitivity or that intermittent self-injection provides better endocrine or physical outcomes.

Research Perspective: No human trial demonstrates that six-, eight-, twelve-, or sixteen-week GHRP-6 cycles build muscle, reduce fat, preserve receptor sensitivity, or improve longevity.

GHRP-6 is frequently discussed alongside other growth hormone secretagogues, GHRH analogues, and experimental tissue-repair compounds. The strongest direct human evidence concerns its interaction with GHRH through complementary endocrine pathways.

GHRH Combination Research: Controlled human studies demonstrate that GHRP-6 and GHRH can amplify GH secretion because they interact with different receptors and physiological pathways.

Overlapping Secretagogues: Combining GHRP-6 with GHRP-2, ipamorelin, or MK-677 targets similar ghrelin receptor biology. There is no evidence that simultaneous stimulation reliably produces superior muscle growth or greater safety.

Appetite Counteracting Strategies: Attempting to offset GHRP-6-related hunger with additional unapproved peptides does not establish improved body composition and may introduce substantial additional risks.

Research Perspective: Demonstrated hormonal interactions do not establish clinically meaningful benefits. No controlled human trial confirms that experimental GHRP-6 combinations improve athletic performance, body composition, organ function, or longevity.

GHRP-6 has a meaningful human endocrine and pharmacokinetic research history, but studies were generally small and focused on short-term measurements. Therefore, its safety profile for repeated use over weeks or months remains inadequately established.

Human Short-Term Tolerability: Early clinical studies generally reported acceptable short-term tolerability under controlled research conditions. However, study sizes and follow-up durations were insufficient to establish safety of prolonged repeated injections.

Hormonal Effects: Certain studies reported increases in cortisol and prolactin during experimental GH stimulation. These effects were not uniform across all protocols and should not be presented as guaranteed at every amount.

FDA Safety Concerns: The FDA lists GHRP-6 in category 2 of its 503B compounding bulk-substance evaluation. Its concerns include possible immunogenicity related to aggregation and peptide-related impurities, cortisol effects, and increased blood glucose associated with decreased insulin sensitivity.

Appetite and Body Composition: Strong hunger-related effects may influence caloric intake. Rat research also reported increased fat accumulation under some experimental conditions, illustrating that GH stimulation is not synonymous with fat loss.

Injection Quality: A research product labeled with high chemical purity is not automatically sterile or free from endotoxins. Product quality and biological tolerability are separate considerations.

Important Limitation: No reliable human adverse-event percentages exist for community-reported six- to twelve-week GHRP-6 injection cycles.

Research Perspective: The available evidence supports cautious interpretation of short-term endocrine tolerability and highlights significant gaps concerning metabolic, immune, and long-term systemic safety.

No FDA-approved contraindication profile exists for GHRP-6 because it has not completed clinical development as a therapeutic drug. Its effects on growth hormone, ghrelin receptor signaling, cortisol, prolactin, appetite, and glucose metabolism create several areas of potential concern.

• Pregnancy and Breastfeeding: Human reproductive, fetal-development, and lactation safety data are insufficient.
• Children and Adolescents: GH-related growth processes require specialized medical management. Experimental GHRP-6 treatment is not an established pediatric therapy.
• Active Cancer: GH and IGF-1 participate in cellular growth pathways. The effects of long-term GHRP-6 exposure during malignancy remain unknown.
• History of Cancer: No adequate human research establishes effects on tumor recurrence or long-term growth-related safety.
• Diabetes: Possible effects on insulin sensitivity and glucose regulation are important concerns.
• Prediabetes / Insulin Resistance: Sustained GH-axis stimulation may complicate metabolic control.
• Obesity: Animal studies demonstrate appetite stimulation and, under certain conditions, increased fat accumulation.
• Sleep Apnea: Long-term GH-axis effects have not been adequately evaluated in people with sleep-disordered breathing.
• Elevated IGF-1: Additional GH stimulation may be undesirable without evaluation of the underlying endocrine condition.
• Pituitary Disorders: GH stimulation responses depend on pituitary function and should be interpreted by appropriate specialists.
• Hyperprolactinemia: Acute prolactin elevation has been demonstrated in some studies.
• Adrenal Disorders: Potential cortisol responses may complicate endocrine interpretation and management.
• Cardiovascular Disease: Effects of chronic exposure on blood pressure, fluid balance, and cardiac function remain unknown.
• Fluid Retention Disorders: Potential GH-axis-related changes in water and sodium balance require caution.
• Kidney Disease: Favorable experimental kidney-injury findings do not establish human treatment effectiveness or safety.
• Liver Disease: Long-term hepatic safety and systemic handling remain inadequately characterized.
• Concurrent GH Secretagogues: Combinations with GHRP-2, ipamorelin, MK-677, or GHRH analogues may increase endocrine effects without established additional benefits.
• Insulin Administration: Hormonal interaction experiments do not justify combining GHRP-6 with insulin. Inappropriate insulin use can cause severe hypoglycemia.
• Competitive Athletics: GHRP-6 is prohibited by the World Anti-Doping Agency under Section S2.2.4.
• Unregulated Injectable Products: Misidentification, peptide impurities, aggregation, microbial contamination, and endotoxins may create serious risks.

Regulatory Status: GHRP-6 is not FDA-approved for growth hormone deficiency, muscle building, fat loss, appetite disorders, cardiac protection, kidney disease, recovery, or anti-aging.

Diagnostic Distinction: GHRP-6 has been investigated experimentally for GH deficiency testing, but it should not be confused with pralmorelin (GHRP-2), which has an approved diagnostic indication in Japan.

FDA Compounding Status: GHRP-6 is listed in category 2 for nominated 503B bulk substances because FDA has identified potential significant safety risks. This does not constitute drug approval or validation of compounded treatment protocols.

Medical Consideration: Suspected growth hormone deficiency, unexplained weakness, progressive muscle loss, abnormal blood glucose, or persistent endocrine symptoms require appropriate clinical evaluation rather than assuming that experimental GH stimulation will provide benefit.

Research involving GHRP-6 has focused on growth hormone secretion, ghrelin receptor signaling, pituitary hormone responses, appetite, glucose metabolism, and experimental organ protection. No validated human monitoring protocol exists for ongoing GHRP-6 use for muscle growth, fat loss, or anti-aging.

GH Measurement Consideration: Growth hormone is naturally secreted in pulses. A single random GH measurement does not reliably establish GH deficiency, GH exposure over time, or treatment effectiveness.

IGF-1 Consideration: IGF-1 provides information about downstream GH-axis signaling, but an increase does not automatically establish muscle growth, improved recovery, or reduced body fat.

Glucose Safety: GH and ghrelin receptor pathways influence metabolic regulation. Changes in glucose and insulin-related measurements may be particularly relevant during prolonged exposure.

Appetite Consideration: Increased hunger does not necessarily produce improved nutritional status or healthy weight gain. Actual food intake and body composition must be assessed independently.

Cardiac and Renal Biomarkers: Findings from experimental injury models do not justify routine specialized cardiac or kidney biomarker testing as a validated measure of GHRP-6 effectiveness.

Important Limitation: No biomarker panel, imaging method, or laboratory monitoring interval has been validated to establish the long-term safety or clinical effectiveness of routine GHRP-6 administration in healthy adults.